Aarti Pharmalabs profit and loss

Latest FY26

Revenue: ₹1,819cr−14.0% on FY25
EBITDA: ₹369cr−20.5% on FY25
Net profit: ₹175cr−35.9% on FY25
EPS: ₹19.27−35.9% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	2,161	1,819	2,115	1,853	1,945	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	8.6	9.7	10.1	4.9	2.3
	2,170	1,829	2,125	1,858	1,948
	1,022	830	887	858	1,014
	56.8	55.9	177	182	281
	−87.5	−51.2	64.2	−19.9	−125
	193	173	162	138	130
	57.3	46.9	26.9	17.2	21.1
	117	104	86.9	73.2	62.5
	490	442	361	307	304
	1,849	1,601	1,765	1,557	1,687
	487	369	464	386	342
	369	265	377	313	280
Profit
	321	228	361	300	261
	−4.8	−2.8	0.0	0.0	0.0
	316	225	361	300	261
	67.6	42.2	67.5	55.8	59.1
	16.3	16.0	20.8	27.8	8.2
	83.9	58.2	88.3	83.6	67.3
	24.7	8.0	0.0	0.0	0.0
	257	175	272	217	193
	232	167	272	217	193
	−7.4	−6.2	−9.8	−0.5	−3.5
	249	168	263	216	190
	253	173	—	216	193
Per share
	₹28.31	₹19.27	₹30.06	₹23.93	₹21.35
	₹28.29	₹19.25	₹30.04	₹23.93	₹21.35
Other comprehensive income — detail
	−7.4	−6.2	−9.8	—	—
	6.5	1.9	9.8	—	—
	—	—	—	0.0	3.5
	0.9	4.3	0.0	—	—
	—	—	—	0.5	0.0
	—	168	—	216	190
Per share — as-filed variants
	₹28.31	₹19.27	₹30.06	₹23.93	₹21.35
	₹28.29	₹19.25	₹30.04	₹23.93	₹21.35
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	1,170	985	987	832	775
	54.1%	54.1%	46.7%	44.9%	39.9%
Adjusted (ex-exceptional items) — derived
	321	228	361	300	261
	−4.8	−2.8	0.0	0.0	0.0
	260	177	272	217	193
	₹28.70	₹19.50	₹30.06	₹23.93	₹21.35

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

AARTIPHARM₹927.65

Aarti Pharmalabs Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersAARTIDRUGS ADVENZYMES AGARWALEYE AKUMS ALIVUS APLLTD CORONA HCGMcap ₹8,410 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Revenue from Operations	1,945.2	1,852.6	2,115.1	1,819.4	2,161.2
Other Income	2.3	4.9	10.1	9.7	8.6
Total Income	1,947.6	1,857.5	2,125.2	1,829.2	2,169.8
Expenses
+ Cost of Materials Consumed	1,014.3	858.4	887.0	830.1	1,021.9
+ Purchases of Stock-in-Trade	280.8	182.2	176.6	55.9	56.8
+ Changes in Inventories	-125.4	-19.9	64.2	-51.2	-87.5
+ Employee Benefit Expense	129.7	138.4	162.0	173.1	193.3
+ Finance Costs	21.1	17.2	26.9	46.9	57.3
+ Depreciation & Amortisation	62.5	73.2	86.9	104.3	117.3
+ Other Expenses	303.7	307.4	360.9	442.3	490.0
Total Expenses	1,686.8	1,557.0	1,764.5	1,601.5	1,849.1
EBITDA	342.0	386.0	464.4	369.2	486.7
EBIT	279.5	312.8	377.5	264.9	369.4
Profit
PBT before Exceptional Items	260.8	300.5	360.7	227.7	320.7
+ Exceptional Items	0.0	0.0	0.0	-2.8	-4.8
Pretax Income	260.8	300.5	360.7	224.9	315.9
+ Current Tax	59.1	55.8	67.5	42.2	67.6
+ Deferred Tax	8.2	27.8	20.8	16.0	16.3
Tax Expense	67.3	83.6	88.3	58.2	83.9
+ Share of Associates & JVs	0.0	0.0	0.0	8.0	24.7
Net Income	193.5	216.9	272.4	174.7	256.7
+ Net Income — Continuing Ops	193.5	216.9	272.4	166.7	232.0
+ Other Comprehensive Income	-3.5	-0.5	-9.8	-6.2	-7.4
Total Comprehensive Income	190.0	216.4	262.6	168.5	249.3
Net Income to Common	193.5	216.4	—	172.7	252.6
Per Share
Basic EPS	21.35	23.93	30.06	19.27	28.31
Diluted EPS	21.35	23.93	30.04	19.25	28.29
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	-9.8	-6.2	-7.4
+ Tax on Items NOT to be Reclassified	—	—	9.8	1.9	6.5
+ Tax on Items NOT to be Reclassified — alt tag	3.5	0.0	—	—	—
+ Tax on Items to be Reclassified	—	—	0.0	4.3	0.9
+ Tax on Items to be Reclassified — alt tag	0.0	0.5	—	—	—
Comprehensive Income — Owners of Parent	190.0	216.4	—	168.5	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	21.35	23.93	30.06	19.27	28.31
Diluted EPS — Continuing Operations	21.35	23.93	30.04	19.25	28.29
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	775.5	831.9	987.2	984.6	1,170.0
Gross Margin %	39.87	44.90	46.67	54.12	54.14
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	260.8	300.5	360.7	227.7	320.7
− Exceptional Items (reconciliation)	0.0	0.0	0.0	-2.8	-4.8
Net Income Adj (tax-effected)	193.5	216.9	272.4	176.8	260.2
EPS Adj	21.35	23.93	30.06	19.50	28.70
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	5.00	5.00	5.00	5.00	5.00
Paid Up Equity Capital	45.3	45.3	45.3	45.3	45.3

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.